Hostname: page-component-69cd664f8f-84qt4 Total loading time: 0 Render date: 2025-03-12T11:33:29.106Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine, relapse and adverse events: 10-year electronic cohort study in Canada: commentary, Kikuchi

Published online by Cambridge University Press:  30 January 2025

Yuki Kikuchi Open the ORCID record for Yuki Kikuchi [Opens in a new window]
Yuki Kikuchi*
Affiliation:
Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Japan; and Department of Psychiatry, Kodama Hospital, Ishinomaki, Japan
*
Correspondence: Yuki Kikuchi. Email: ykikuchi@sand.ocn.ne.jp
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Clozapinerelapseadverse eventscohort studyCanada
Type
Commentary
Information
The British Journal of Psychiatry , Volume 226 , Issue 1 , January 2025 , pp. 53 - 54
Check for updates
Copyright
Copyright © The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Balbuena, L, Halayka, S, Lee, A, Ahmed, AG, Hinz, T, Kolla, N, et al. Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada. Br J Psychiatry [Epub ahead of print] 18 Sep 2024. Available from: https://doi.org/10.1192/bjp.2024.140.Google Scholar
Tiihonen, J, Taipale, H, Mehtala, J, Vattulainen, P, Correll, CU, Tanskanen, A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019; 76: 499–507.CrossRefGoogle ScholarPubMed
Taipale, H, Mehtala, J, Tanskanen, A, Tiihonen, J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia – a nationwide study with 20-year follow-up. Schizophr Bull 2018; 44: 1381–7.CrossRefGoogle ScholarPubMed
Taipale, H, Tanskanen, A, Mehtala, J, Vattulainen, P, Correll, CU, Tiihonen, J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020; 19: 61–8.CrossRefGoogle Scholar
Stroup, TS, Gerhard, T, Crystal, S, Huang, C, Olfson, M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016; 173: 166–73.CrossRefGoogle ScholarPubMed
Weiser, M, Davis, JM, Brown, CH, Slade, EP, Fang, LJ, Medoff, DR, et al. Differences in antipsychotic treatment discontinuation among veterans with schizophrenia in the U.S. Department of veterans affairs. Am J Psychiatry 2021; 178: 932–40.CrossRefGoogle ScholarPubMed
Vanasse, A, Blais, L, Courteau, J, Cohen, AA, Roberge, P, Larouche, A, et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand 2016; 134: 374–84.CrossRefGoogle ScholarPubMed
Luykx, JJ, Correll, CU, Manu, P, Tanskanen, A, Hasan, A, Tiihonen, J, et al. Pneumonia risk, antipsychotic dosing, and anticholinergic burden in schizophrenia. JAMA Psychiatry 2024; 81: 967–75.CrossRefGoogle ScholarPubMed
Partanen, JJ, Happola, P, Kampe, A, Ahola-Olli, A, Hellsten, A, Rask, SM, et al. High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-year follow-up register study. Am J Psychiatry 2024; 181: 879–92.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.